The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Investing.com - Copenhagen-listed shares in Novo Nordisk (CSE: NOVOb) surged on Friday after the Danish drugmaker said ...

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine. The lawsuit, filed ...

Health Canada has issued a recall notice for compounded drugs containing semaglutide, which is a key component in popular medications like Ozempic and Wegovy.

Linden Thomson, senior fund manager at Candriam, notes that weight-loss drugs have become the driver of healthcare investing.

Multiple studies had already shown that their benefits might go beyond weight loss and diabetes. Those studies showed that patients taking GLP-1 medication fared better against a wide range of health ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

The City of Greensboro, North Carolina, which provides public safety, emergency, and health services to over 300,000 residents and spends millions annually on insulin medications, filed a lawsuit last ...